Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the median initial dose in those who did not reach the target concentration was 15.8 mg/kg per day; this result suggests that higher initial doses might be warranted.
Posaconazole is currently approved by the US Food and Drug Administration for prophylaxis against invasive fungal infection (IFIs) in high-risk severely immunocompromised patients aged 13 years or older [1] . However, because pediatric patients represent a diverse population with many pharmacokinetic and pharmacodynamic differences, the limited data on its use for prophylaxis against and treatment of IFIs creates a clinical challenge.
Döring et al. [2] reported their experience with posaconazole prophylaxis in 60 patients aged ≤12 years. They compared their initial dosing strategy of 5 mg/kg orally twice daily to a strategy of 4 mg/kg orally 3 times daily and found median trough concentrations of 134 and 383 µg/mL, respectively. Bernardo et al. [3] retrospectively evaluated posaconazole dosing strategies of 18 to 24 mg/kg per day in patients who weighed <34 kg and 800 mg/day in patients who weighed ≥34 kg for treatment of IFI. Patients with a plasma concentration of <0.7 µg/mL had received appreciably lower doses per kilogram than those with a trough concentration of ≥0.7 µg/mL (median, 12.9 vs 20 mg/ kg per day, respectively; P = .02).
Definitive correlations between posaconazole concentration and efficacy in pediatric patients have not been established [4] . Some data suggest that higher plasma concentrations might be associated with improved responses in adults, and some pharmacokinetic models recommend a concentration of ≥0.7 µg/mL to minimize risk of breakthrough infection [5] [6] [7] . We sought to investigate the initial dose needed to achieve a posaconazole concentration of 0.7 µg/mL in pediatric patients. We also sought to assess, as secondary objectives, any correlations between patient age and ability to achieve target posaconazole concentrations with the initial dosing regimen and toxicities associated with posaconazole.
METHODS
This was a single-center retrospective study to examine posaconazole in pediatric patients with cancer from January 2007 through December 2014. Approval was granted by the Memorial Sloan Kettering Cancer Center Institutional Review Board. Included were patients between ≥1 and ≤18 years old who received posaconazole for a minimum of 5 consecutive days, had a steadystate posaconazole predose concentration (C trough ) measured after 5 days of initial therapy, and had received the suspension or tablet formulation. Patients >18 years old, patients who received posaconazole for <5 consecutive days, and patients who received intravenous posaconazole were excluded. Posaconazole concentrations were measured from plasma via liquid chromatography-tandem mass spectrometry (analytical range, 0.2-10 µg/mL) by a reference laboratory until May 2014, at which time the use of an in-house assay was implemented. During the study period, patients at our institution who were <13 years old were typically initiated on a dose of 10 and 12 mg/kg per day, whereas patients ≥13 years old received 600 to 800 mg per day for prophylaxis or treatment, respectively.
Success of the initial posaconazole dose was defined as achievement of a steady-state concentration of 0.7 µg/L with the initial dosing regimen. Because of different dosing frequencies for posaconazole, all data on patient doses collected within the study were converted to milligrams/kilogram per day to enable weight-based dose comparisons between the patients. IFI was defined according to the European Organization for Research and Treatment of Cancer consensus definitions [8] . The data collected included baseline characteristics, initial posaconazole dose, posaconazole concentrations, results from radiological e150 • JPIDS 2017:6 (September) • BRIEF REPORT examinations, cultures, and serum bronchoalveolar lavages, galactomannan antigen levels, 1,3-β-d-glucan levels, liver function test (LFT) results, electrocardiogram results, and concomitant medications. Differences in initial posaconazole concentrations were compared between groups using the Wilcoxon rank-sum test.
RESULTS
Thirty-two patients met the inclusion criteria for this analysis. Patient ages ranged from 3 to 18 years, and all the patients received the suspension formulation of posaconazole. The majority of patients had a hematologic primary diagnosis ( Table 1) . Fifteen patients received posaconazole for an indication of prophylaxis and 17 for treatment. European Organization for Research and Treatment of Cancer consensus definitions for IFI were not met in 5 of these 17 patients despite the clinical impression [8] .
The median initial dose for the entire cohort was 17.5 mg/kg per day. Of the 32 patients, 16 achieved the target concentration of ≥0.7 µg/mL after a median initial dose of 22.8 mg/kg per day (range, 9.2-44 mg/kg per day). The remaining 16 patients did not achieve the target concentration after a median initial dose of 15.8 mg/kg per day (range, 9.3-50 mg/kg per day) ( Table 1) . We found no statistical differences between the initial dose of those who achieved the target concentration of 0.7 µg/mL and those who did not.
The median initial doses within this analysis also were assessed according to patient age (Table 1) . Patients <13 years old in whom a target concentration of 0.7 µg/mL was achieved had a higher initial median dose than those who did not, but no differences were found in patients ≥13 years old. For the patients <13 years old, 12 of 22 (55%) achieved a concentration of 0.7 µg/mL, compared to 4 of 10 (40%) in patients >13 years. The small patient numbers in each subgroup did not allow for statistical analysis.
Of the 15 patients who received posaconazole for prophylaxis, 1 patient developed a proven breakthrough fungal infection. The patient was an 11-year-old girl initiated on posaconazole at a dose of 15.6 mg/kg per day while she was severely neutropenic; her subsequent plasma concentration was 0.31 µg/mL. The patient developed a cutaneous mold infection and had an elevated 1,3-β-d-glucan level and a rising serum galactomannan level, which raised suspicion for a disseminated fungal infection. The patient never regained a neutrophil count and ultimately died as a result of multiple infections.
These patients were assessed at baseline and 2 weeks after posaconazole initiation for the presence of grade ≥2 liver toxicity by using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [9] . Of 30 patients who received posaconazole for at least 14 days, 9 had grade 2 liver toxicity at day 14. Of these 9 patients, 3 had baseline grade 2 liver abnormalities before posaconazole initiation. The median initial posaconazole dose in patients with grade ≥2 liver toxicity was the same as that in patients who did not have grade 2 liver toxicity (median for both groups, 17.5 mg/kg per day; P = .37). A sensitivity analysis in which patients who had baseline grade ≥2 LFT abnormalities were excluded had similar results. To better characterize the LFT changes in the patients with baseline liver abnormalities, the net changes in LFT results were assessed. After 14 days of posaconazole, 2 patients had a net decrease in LFT values, whereas 1 patient had a net increase in their LFTs (CTCAE grade 3 liver toxicity). Data from baseline and posttreatment electrocardiograms were collected, but routine testing was not performed, and data were available for only 14 patients in the cohort. Among these 14 patients, only 1 had an elevated QTc grade ≥2 toxicity according to CTCAE 4.03; however, this patient was concurrently on ondansetron and levofloxacin. Overall, we documented no discontinuations that resulted from toxicity. Our patients were routinely counseled to coadminister posaconazole suspension with high-fat dietary intake or ginger ale, but adherence could not be determined because 22 patients in the analysis were outpatient. Eighteen patients were concurrently on acid-suppressing agents while they received posaconazole; 10 of these patients did not achieve the initial goal concentration. However, conclusions regarding the effect of concurrent acid-suppressant use cannot be evaluated.
DISCUSSION
Data on the use of posaconazole in the pediatric population remain limited. In this study, we examined the use of posaconazole in patients as young as 3 years, and approximately twothirds of the patients in the analysis were <13 years of age, which demonstrates the clinical need for more robust data on appropriate dosing strategies in our younger pediatric patients.
In our analysis, the median initial posaconazole dose in patients who achieved a therapeutic concentration was higher than that in the patients who did not (22.8 vs 15.8 mg/kg per day, respectively); however, this difference was not statistically significant. The power to detect such a difference might be limited by the relatively small sample size. Similar differences were observed in patients <13 years old; the median initial dose in patients who achieved a therapeutic plasma concentration was 27.9 mg/kg per day compared to 17.7 mg/kg per day in patients who did not reach the target plasma concentration. Because of the small sample size, a statistical assessment was not performed within this subgroup analysis, but the disparity in these median initial doses suggests that patients less than 13 years of age require appreciably higher initial doses of posaconazole to achieve a plasma concentration of ≥0.7 µg/mL. Consistent with data reported previously by Bernardo et al. [3] , patients ≥13 years old were no more likely to achieve a posaconazole concentration of ≥0.7 µg/mL when they used currently recommended doses.
There were several limitations to this retrospective analysis. With only 1 patient with breakthrough IFI, correlations between subtherapeutic concentrations and breakthrough fungal infection could not be evaluated. Dosing frequencies varied between every 6 and every 12 hours (Table 1) , which is a possible confounding factor that we did not assess. We included pediatric patients who received a minimum of 5 days of posaconazole on the basis of the hypothesis that, although the reported mean half-life is 35 hours in adult patients, the pediatric rate of elimination is likely faster.
In conclusion, the results of our analysis emphasize the need for stronger pharmacokinetic and pharmacodynamic data on the use of posaconazole in patients <13 years of age and suggest that initial dosing strategies of ≥20 mg/kg per day with appropriate pharmacokinetic monitoring could be used in this younger patient population.
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